Gold stages rebound on dollar weakness; US, EU ink tariff deal
Spot gold was up 0.2% at $3,342.62 per ounce, as of 0421 GMT, after touching its lowest level since July 17. U.S. gold futures edged 0.2% higher to $3,342.90.
The U.S. struck a framework trade agreement with the European Union on Sunday, imposing a 15% import tariff on most EU goods - half the threatened rate - and averting a bigger trade war between the two allies that account for almost a third of global trade.
However, the agreement left key issues unresolved, including tariffs on spirits.
The agreement eased transatlantic trade tensions, putting pressure on gold, said Jigar Trivedi, a senior commodity analyst at Reliance Securities, adding that it also softened the dollar index, which provided some cushion to bullion.
The U.S. dollar index (.DXY), opens new tab eased 0.1%, making greenback-priced bullion more affordable for overseas buyers.
Risk sentiment improved following the agreement, with European currencies and U.S. stock index futures trading higher.
Meanwhile, senior U.S. and Chinese negotiators are set to meet in Stockholm later in the day to address long-standing economic disputes, seeking to extend a truce that has prevented higher tariffs.
"In the short term, we don't expect gold to experience wild swings. Investors are turning their focus to a pivotal week for U.S. monetary policy and economic data," Trivedi said.
The Federal Reserve is expected to maintain its benchmark interest rate in the 4.25%-4.50% range after its two-day policy meeting concludes on Wednesday.
U.S. President Donald Trump said on Friday he had a positive meeting with Powell, suggesting the Fed chief might be inclined to lower interest rates.
Spot silver was up 0.2% at $38.21 per ounce, while platinum gained 1.2% to $1,417.67 and palladium rose 2.9% to $1,254.98.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Telegraph
16 minutes ago
- Telegraph
AI researcher ‘turns down $1bn pay offer from Mark Zuckerberg'
A tech worker has reportedly turned down a $1bn (£750m) pay deal to join Mark Zuckerberg's artificial intelligence (AI) unit amid an escalating war for talent in Silicon Valley. Mr Zuckerberg's Meta reportedly offered several researchers who work at Thinking Machines, a San Francisco-based AI start-up, packages worth hundreds of millions of dollars to join the social media giant. One of those packages would have been worth as much as $1bn over several years, according to a report from Wired, while some researchers were also offered between $200m and $500m over a four-year period. Most deals included an award worth $50m to $100m in the first year. So far, no staff at the start-up have taken up an offer from Meta. Last month, Thinking Machines raised $2bn at a $12bn valuation, despite having no product. A spokesman for Meta disputed the claims, although confirmed it had made a 'handful' of offers to staff at Thinking Machines. 'We made offers only to a handful of people at Thinking Machines and while there was one sizeable offer, the details are off,' the spokesman said. Thinking Machines was founded by 36-year-old Mira Murati, a former OpenAI executive who has become one of the powerful women in tech since launching the company. AI arms race The eye-watering pay offers come amid an AI arms race, with tech giants trying to tempt leading AI scientists and programmers to join their efforts over those of rivals. Sam Altman, the chief executive of OpenAI which owns ChatGPT, previously claimed Meta had offered his staff deals worth as much as $100m. Mr Zuckerberg has been personally leading a recruitment drive to attract leading scientists and developers to a new lab within Meta in a race against rivals to build highly powerful AI tools. The Meta chief executive has reportedly been reaching out to dozens of targets with personalised WhatsApp messages and bumper pay deals. Meta is spending tens of billions of dollars on AI data centres that will be used to help create more powerful machine-learning tools that Mr Zuckerberg has claimed could soon transform the economy and society. He has also already recruited around 50 leading researchers and experts for a new 'superintelligence' lab within Meta, after growing frustrated at the lack of progress by his own engineers. Earlier this year, Meta delayed a major update to its AI technology, dubbed Behemoth. Mr Zuckerberg also engineered a $14.3bn deal to poach Alexandr Wang, the founder of AI business Scale AI, to lead his new team, acquiring a 49pc stake in the start-up in the process.
Reuters
16 minutes ago
- Reuters
US FDA's top vaccine official Vinay Prasad leaves agency after short stint
July 29 (Reuters) - The U.S. Food and Drug Administration's top official, Vinay Prasad, has left the agency after nearly three months as Director of the Center for Biologics Evaluation and Research, a government spokesperson said late on Tuesday. Prasad, an oncologist who previously criticized the FDA and was a fierce critic of U.S. COVID-19 vaccine and mask mandates, had been appointed in May. "Dr. Prasad did not want to be a distraction to the great work of the FDA in the Trump administration and has decided to return to California and spend more time with his family," a spokesperson from the Department of Health and Human Services told Reuters in an emailed statement. Endpoints News first reported Prasad's departure. His exit comes after a number of unusual regulatory actions, including those taken recently by the agency on Sarepta Therapeutics'(SRPT.O), opens new tab gene therapy, Elevidys. "Unprecedentedly, there were multiple press leaks from the FDA, negatively impacting (its) credibility," said BMO Capital Markets analyst, Koustas Billouri. During Prasad's short stint, the U.S. FDA limited the use of COVID-19 vaccines and declined to approve therapies from Replimmune (REPL.O), opens new tab and Capricor Therapeutics (CAPR.O), opens new tab. The regulator's decisions under Prasad raised concerns that he was anti-patient choice, Jefferies analyst Roger Song said, adding that investors will see his departure as a positive for gene therapy and vaccine makers. The Nasdaq Biotechnology Index (.NBI), opens new tab declined 7% on Prasad's appointment, but has since recovered. Shares of Replimmune rose 58%, Sarepta was up 11.2% and Capricor added 21.2% in premarket trading on Wednesday. Prasad also held the additional role of the agency's chief medical and science officer, to which he was appointed last month, according to STAT News. Nominating a more seasoned official to replace him could help the FDA rebuild its credibility, BMO's Billouri said.
Reuters
16 minutes ago
- Reuters
Indian airline IndiGo posts lower first-quarter profit as forex losses widen
July 30 (Reuters) - IndiGo airline operator Interglobe Aviation ( opens new tab reported a drop in first-quarter profit on Wednesday, hurt by higher costs as foreign exchange losses ballooned. India's biggest airline by market share reported a profit of 21.61 billion rupees ($247.2 million) for April-June period, down from 27.27 billion rupees a year ago. ($1 = 87.4230 Indian rupees)
